Aurinia Pharmaceuticals (AUPH) PT Lowered to $22 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq rise as tech stocks gain ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts AUPH Hot Sheet
Price: $16.58 +2.73%
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 16 | New: 12
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 16 | New: 12
Join SI Premium – FREE
RBC Capital analyst Douglas Miehm lowered the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $22.00 (from $27.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Essential Properties Realty Trust (EPRT) PT Lowered to $31 at Cantor Fitzgerald
- Vertex (VRTX) PT Raised to $619 at Cantor Fitzgerald
- Aurinia Pharmaceuticals (AUPH) PT Raised to $18 at RBC Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
